Here are five points:
1. The company plans to use the funding to boost the commercialization of its cervical fusion technology portfolio.
2. London, U.K.-based MVM Life Science Partners, a new investor, led the financing. The company is now a part of Providence’s board of directors.
3. Jupiter, Fla.-based Stanmore Medical Investments and Mill Valley, Calif.-based Aphelion Capital also participated in the financing round.
4. Providence develops tissue-sparing, cervical fusion technology.
5. The company is currently working on commercializing the DTRAX platform of single-use, tissue-sparing instruments and CAVUX implants for cervical fusion.
More articles on devices:
Zimmer Biomet’s growth strategy in spine: MIS, cervical and becoming a ‘health solutions provider’
Predictive Technology Group highlights US patent allowance for treating patients with genetic spinal deformities, syndromes: 5 highlights
Global wearable medical devices market to hit $12.1B by 2021: 9 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
